Skip to main content

Table 1 Patient characteristics

From: Comparison of different methods for post-therapeutic dosimetry in [177Lu]Lu-PSMA-617 radioligand therapy

Characteristics n (%)/mean [min–max]
Age 71 [61–88]
Pretherapeutic PSA value [ng/ml] 591 [14–3277]
Pretherapeutic ECOG PSa
 0 7 (29.2%)
 1 16 (66.7%)
 2 1 (4.2%)
Previous treatments
 Prostatectomy 11 (45.8%)
 Radiation 15 (62.5%)
 Androgen deprivation therapy 24 (100%)
 Enzalutamide or abiraterone 23 (95.8%)
  Enzalutamide 20 (83.3%)
  Abiraterone 22 (91.7%)
  Enzalutamide and abiraterone 19 (79.2%)
 Chemotherapy 19 (79.2%)
  Docetaxel 19 (79.2%)
  Cabazitaxel 8 (33.3%)
  Docetaxel and cabazitaxel 8 (33.3%)
223Ra therapy 8 (33.3%)
153Sm therapy 1 (4.2%)
Sites of metastases
 Bone 24 (100%)
 Lymph node 18 (75%)
 Other 10 (41.7%)
Tumor load according to [25]
 High 11 (45.8%)
 Medium 13 (54.2%)
 Low 0 (0 %)
  1. aEastern Cooperative Oncology Group Performance Status